Vorapaxar in the secondary prevention of atherothrombotic events.

@article{Morrow2012VorapaxarIT,
  title={Vorapaxar in the secondary prevention of atherothrombotic events.},
  author={David A. Morrow and Eugene Braunwald and Marc P. Bonaca and Sebasti{\'a}n Francisco Ameriso and Anthony John Dalby and Mary Polly Fish and Keith A. A. Fox and Leslie J Lipka and Xuan Liu and Jos{\'e} Carlos Nicolau and Antonius Oude Ophuis and Ernesto A. C. Paolasso and Benjamin M. Scirica and Jindrich Spinar and Pierre Th{\'e}roux and Stephen D. Wiviott and John T. Strony and Sabina A. Murphy},
  journal={The New England journal of medicine},
  year={2012},
  volume={366 15},
  pages={1404-13}
}
BACKGROUND Thrombin potently activates platelets through the protease-activated receptor PAR-1. Vorapaxar is a novel antiplatelet agent that selectively inhibits the cellular actions of thrombin through antagonism of PAR-1. METHODS We randomly assigned 26,449 patients who had a history of myocardial infarction, ischemic stroke, or peripheral arterial disease to receive vorapaxar (2.5 mg daily) or matching placebo and followed them for a median of 30 months. The primary efficacy end point was… CONTINUE READING
Highly Influential
This paper has highly influenced 15 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS
254 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 254 extracted citations

Similar Papers

Loading similar papers…